Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

被引：0
|
作者：
Ignacio Bernabéu
Carmen Fajardo
Mónica Marazuela
Fernando Cordido
Eva María Venegas
Pedro de Pablos-Velasco
Gonzalo Piedrola Maroto
María Pilar Olvera
Isabel Pavón de Paz
Davide Carvalho
Carme Romero
Guillermo De la Cruz
Cristina Álvarez Escolá
机构：
[1] Hospital Clínico Universitario Santiago de Compostela,Endocrinology and Nutrition Department
[2] Hospital Universitario de La Ribera,Endocrinology and Nutrition Department
[3] Hospital Universitario La Princesa,Endocrinology and Nutrition Department
[4] Universidad Autónoma Madrid,Faculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department
[5] Instituto Princesa,Endocrinology and Nutrition Department
[6] Complejo Hospitalario Universitario de A Coruña,Endocrinology and Nutrition Department
[7] Hospital Universitario Virgen del Rocío,Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João
[8] University of Las Palmas de Gran Canaria. Spain,Endocrinology and Nutrition Department
[9] Endocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves,undefined
[10] Endocrinology and Nutrition Departament,undefined
[11] Hospital Universitario Nuestra Señora de Candelaria,undefined
[12] Endocrinology and Nutrition Departament,undefined
[13] Hospital Universitario de Getafe,undefined
[14] Faculty of Medicine,undefined
[15] i3S,undefined
[16] Universidade do Porto,undefined
[17] Adknoma Health Research S.L.,undefined
[18] Ipsen Pharma,undefined
[19] Hospital Universitario La Paz,undefined
来源：
Endocrine | 2020年 / 70卷
关键词：
Acromegaly; Lanreotide; Insulin-like growth factor 1; Somatostatin; Growth hormone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：575 / 583
页数：8
相关论文
共 50 条
  • [41] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Daphne T. Adelman
    Dirk Van Genechten
    Clémentine M. Megret
    Xuan-Mai T. Truong Thanh
    Philippa Hand
    Wendy A. Martin
    Advances in Therapy, 2019, 36 : 3409 - 3423
  • [42] Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
    Adelman, Daphne T.
    Van Genechten, Dirk
    Megret, Clementine M.
    Thanh, Xuan-Mai T. Truong
    Hand, Philippa
    Martin, Wendy A.
    ADVANCES IN THERAPY, 2019, 36 (12) : 3409 - 3423
  • [43] Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
    Philippe J. Caron
    John S. Bevan
    Stephan Petersenn
    Aude Houchard
    Caroline Sert
    Susan M. Webb
    Pituitary, 2016, 19 : 149 - 157
  • [44] Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
    Caron, Philippe J.
    Bevan, John S.
    Petersenn, Stephan
    Houchard, Aude
    Sert, Caroline
    Webb, Susan M.
    PITUITARY, 2016, 19 (02) : 149 - 157
  • [45] Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-) NET: Update from the CLARINET Open-Label Extension (OLE) Study
    Caplin, M.
    Pavel, M.
    Cwikla, J. B.
    Phan, A. T.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wolin, E. M.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P. B.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 123 - 123
  • [46] LanroNET - A Non-Interventional Prospective Study to Assess the Resource Utilisation and Cost of Lanreotide Autogel 120 mg in the Population of Polish Patients with Symptomatic Neuroendocrine Tumours
    Orlewska, Ewa
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    Budlewski, Tadeusz
    Jessa-Jablonska, Maria
    Houchard, Aude
    Bednarczuk, Tomasz
    ENDOKRYNOLOGIA POLSKA, 2018, 69 (05) : 567 - 572
  • [47] Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly
    Cozzi R.
    Barausse M.
    Sberna M.
    Lodrini A.
    Franzini A.
    Lasio G.
    Attanasio R.
    Pituitary, 2000, 3 (4) : 231 - 238
  • [48] Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naive to somatostatin-receptor ligands: analysis of three multicenter clinical trials
    Alquraini, Hussain
    Schneider, Maria del Pilar
    Mirakhur, Beloo
    Barkan, Ariel
    PITUITARY, 2018, 21 (03) : 283 - 289
  • [49] Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-)NETs: Post Hoc Analyses from the CLARINET Study
    Caplin, M.
    Pavel, M.
    Cwikla, J. B.
    Phan, A. T.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wolin, E. M.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P. B.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 123 - 123
  • [50] Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials
    Hussain Alquraini
    Maria del Pilar Schneider
    Beloo Mirakhur
    Ariel Barkan
    Pituitary, 2018, 21 : 283 - 289
12345